D-甘露糖 D-Mannose × 尿路感染

結論:證據支持但有警示

D-Mannose is not covered by Examine (coverage gap, L1 found=false), so the grade rests on primary evidence and authoritative bodies.

C 🟠 C 薄弱證據 附警語發布 ⚠️ medium — moderate promotional content
⚠️ 標記 🇹🇼 台灣在地警示

D-Mannose is not covered by Examine (coverage gap, L1 found=false), so the grade rests on primary evidence and authoritative bodies. The L2 PubMed corpus shows a sharp methodological split: the older open-label Kranjcec 2014 RCT (n=308) showed a strong protective effect comparable to nitrofurantoin, but the much larger and rigorously designed double-blind MERIT 2024 trial (n=598, JAMA Intern Med) was null (RR diff -5%, p=0.26), and the two 2025 meta-analyses both produced non-significant pooled estimates (RR 0.44-0.57, CI crossing 1, I-squared up to 90%). Cochrane 2022 graded certainty as very low. Authoritative bodies reinforce a cautious-to-negative reading: AUA/CUA/SUFU 2025 Statement 14 (Moderate Rec, Grade B) explicitly states D-mannose monotherapy may not be effective; EFSA rejected the only D-mannose-containing UTI health claim in 2009; NHS/NICE describe it as self-care with mixed evidence and FDA issued a warning letter against UTI-prevention claims. Safety is acceptable (minor GI effects, no major drug interactions per L9) and a low-risk trial is defensible (Harvard L5d position), so the evidence is best characterized as mixed and leaning negative rather than wholly refuted, supporting a Grade C.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.48
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
81%
證據方向一致性高
證據層級
E1
Cochrane 高品質系統性回顧/統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
L5 臨床機構權威立場
0.55
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.485
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial (MERIT)
PMID: 38587819 2024 RCT (double-blind) n = 598
結論:51.0% in D-mannose group vs 55.7% in placebo experienced subsequent UTI; risk difference -5% (95% CI -13% to 3%, p=0.26). D-Mannose did NOT reduce recurrent UTI in primary care.
🟢 高品質 政府資助 效應量:Risk difference -5%; 95% CI -13% to 3%; non-significant
前往 PubMed
D-Mannose for prevention of recurrent urinary tract infection in adult women: An updated systematic review and meta-analysis of randomized controlled trials
PMID: 41195062 2025 統合分析 n = 890
結論:Pooled RR 0.44 (95% CI 0.18-1.11, p=0.082) — non-significant. High heterogeneity I²=90%. Authors conclude prophylaxis with D-mannose did not produce a statistically significant difference in recurrent UTI risk.
效應量:RR 0.44; 95% CI 0.18-1.11; NS
前往 PubMed
Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials
PMID: 41004704 2025 統合分析 n = 1,167
結論:D-mannose vs control: RR 0.57 (95% CI 0.29-1.15); D-mannose vs antibiotics: RR 0.39 (95% CI 0.12-1.25). Neither comparison reached significance. In postmenopausal women specifically RR 0.94 (0.79-1.12).
效應量:RR 0.57; 95% CI 0.29-1.15; NS
前往 PubMed
D-mannose for preventing and treating urinary tract infections (Cochrane Review)
PMID: 36041061 2022 Cochrane SR n = 719
結論:「Little to no evidence to support or refute the use of D-mannose to prevent or treat UTIs in all populations.」 Certainty of evidence rated very low across comparisons due to methodological limitations and heterogeneity.
🟢 高品質 效應量:No pooled estimate — very low certainty
前往 PubMed
D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial (Kranjcec et al.)
PMID: 23633128 2014 RCT (open-label) n = 308
結論:UTI recurrence: D-mannose 14.6%, nitrofurantoin 20.4%, no-prophylaxis 60.8%. D-mannose significantly reduced UTI vs no prophylaxis (RR 0.24, p<0.001), comparable to nitrofurantoin. Side effects: D-mannose 8.2% vs nitrofurantoin 30.2%.
🟠 品質有限 效應量:RR 0.24 (vs no prophylaxis); NS vs nitrofurantoin
前往 PubMed

L4a US FDA
謹慎
Advanced U-Tract consists of D-mannose, which is used to help prevent bacteria from adhering to the walls of the urinary tract and reduce the occurrence of urinary tract infections. ... Therefore, this product is intended for treatment of diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. As such, adequate directions cannot be writt… 來源↗
L4b EU EFSA
反對
L4c UK NHS
謹慎
D-mannose – a sugar you can buy as a powder or tablets to take every day 來源↗
L4d TW TFDA / 衛福部
中性
D-甘露糖屬自然界存在的單糖,為葡萄糖異構體,可以從植物與微生物中獲得,被廣泛應用於食品、化妝品以及醫藥業等領域。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
中性
— 本適應症無對應資料
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
中性
L5d Harvard Health
中性
L5e Specialty Society (condition-mapped)
中性

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

台灣女性社群(PTT WomenTalk / e-shopping / regimen 為主,藥師版有一篇技術性討論)對 D-甘露糖預防反覆尿道炎多持正面態度,普遍認知它定位是『預防/保養』而非治療急性感染,急性發作仍需抗生素。多人強調足量(每日約 2000mg 以上)才有感,且常與蔓越莓、益生菌做成複方比較;不少人反映復發頻率下降,少數人覺得無感。社群也再三提醒喝水、不憋尿才是根本。討論中混雜可觀的保健品業配與『N 款評比』推薦文,需留意立場。

💬社群實感

多數正面(多人反映規律足量服用後復發頻率下降;少數反映無感)

破解迷思 社群最常見的 5 個誤解
事實把『預防保養』當成『治療』,以為急性發作可只靠甘露糖而延誤抗生素就醫
事實以為蔓越莓(或單喝蔓越莓汁)就等同甘露糖、效果相同,忽略市售蔓越莓常吃不到顯著劑量
事實誤以為甘露糖對所有泌尿道感染都有效,忽略它主要針對大腸桿菌(E. coli)造成的感染
事實認為劑量越低或隨便吃就有效,忽略社群與研究都指向需足量(約 2000mg/日)才有感
事實把『私密處保養』與『尿路感染預防』混為一談(陰道感染與泌尿道感染機轉不同)
🩹 社群通報的副作用
  • 粉劑口感偏乾、易嗆到(最常見的小抱怨,需分次配水服用)
  • GNC 膠囊款打嗝會有膠囊味
  • 整體罕見明顯不良反應;研究指出吸收差、不影響血糖,社群亦少見血糖或肝腎疑慮回報
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • 大研生醫(淨密樂甘露糖蔓越莓益生菌,社群最常被提到的複方)
  • GNC(甘露糖+蔓越莓,常見進口選擇)
  • 愛美仕(淨舒逸甘露醣,主打單包 2000mg 高劑量)
  • 優露分(被點名為每 1000mg 最便宜)
  • BHK's
  • Costco/iHerb 自購進口款
  • 極美計畫、營養師輕食

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

「全台唯一添加 De-UTI® mannose D-甘露糖配方 1000mg,搭配 300 倍高濃縮法國 dianafood 專利蔓越莓萃取物、義大利專利 5 隻益生菌」 NT$552/24 包

代表來源 ↗
L10b · TFDA 法定身份 官方認定

「甘露糖有許多益處,因國內食品法規範,不得聲稱療效」

來源 ↗

  • 抗生素治療
  • 行為與衛生措施(增加水分攝取、排尿習慣)
  • 停經後女性陰道局部雌激素治療
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v23 engine_version: v1.0 claim_id: CLM-COND-uti-INT-d-mannose-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-uti-INT-d-mannose-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "D-甘露糖能改善尿路感染",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}